Top

Published in:

Open Access 01-12-2012 | Meeting abstract

T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting

Author: Yangqiu Li

Published in: Journal of Hematology & Oncology | Special Issue 1/2012

Excerpt

Poor cellular immune function may relate to carcinogenic processes and to worse prognosis in solid tumor patients as well as in leukemia. Moreover, the progression of tumor might further induce the cellular immune suppression. Therefore, a set of molecular immunological techniques to analyze and monitor the changes of host T-cell immune status is needed, which can fully characterize the feature of T-cell immunodeficiency in different malignancies, providing information and direction for immune reconstruction, in particular for enhancement the specific anti-tumor immune function. …

Krell PFI, Weber S, Reuther S, Gombert M, Keller T, Schuster FR, Asang C, Stoye J, Borkhardt A, Fischer U: Next Generation Sequencing Spectratyping (NGS-S) Comprehensively Monitors T Cell Receptor Diversity in Children with T Cell Abnormalities. ASH Annual Meeting Abstracts. 2011, 118 (21): #2173-

Xuan L, Xiuli Wu X, Liu Q, Zhang Y, Fan Z, Li Y, Ling Y: G-CSF Affects the Distribution and Clonality of TRGV and TRDV Repertoire of T Cells and the Expression Pattern of CD3 Genes. ASH Annual Meeting Abstracts. 2011, 118 (21): #1946-

Wu X, Zhu K, Du X, Chen S, Yang L, Wu J, Liu Q, Li Y: Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2011, 4: 19-10.1186/1756-8722-4-19.PubMedCentralCrossRefPubMed

Brown J, Kim HT, Cutler C, McDonough S, Alyea E, Ho V, Attar EC, Dey BR, McAfee SL, Spitzer T: Immune Reconstitution After Cord Blood Transplantation in Adults Depends on Activity of Thymic Epithelial Cells and Vascular Endothelial Elements. ASH Annual Meeting Abstracts. 2011, 118 (21): #4075-

Porter DL: Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. ASH Education Program Book. 2011, 2011 (1): 292-298.

Zhang M, Sukhumalchandra P, Enyenihi AA, St. John LS, Hunsucker SA, Ruisaard K, Atrache Z, Ropp PA, Rodriguez-Cruz T, Mittendorf E: A Novel HLA-A2 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target for Myeloid Leukemia. ASH Annual Meeting Abstracts. 2011, 118 (21): #2986-

Zohren F, Imperato MR, Usanarat A, Spencer DM, Heslop HE, Brenner MK, Rooney CM, Leen AM, Vera JF, Gerdemann U: Genetic Modification of Multi Leukemia Antigen-Specific Cytotoxic T Lymphocytes (CTL) to Enhance In Vivo Safety and Persistency. ASH Annual Meeting Abstracts. 2011, 118 (21): #644-

Weber G, Gerdemann U, Hensel NF, Leen AM, Bollard CM, Barrett AJ: Generation of Multi-Antigen Specific T Cells for Adoptive Immunotherapy of Myeloid Leukemia and Identification of MHC Class I and II-Restricted Peptides for WT1, Proteinase 3 and Human Neutrophil Elastase. ASH Annual Meeting Abstracts. 2011, 118 (21): #2985-

Bao L, Cowan MJ, Dunham K, Horn BN, McGuirk J, Gilman A, Lucas K: Adoptive Immunotherapy with CMV Specific Cytotoxic T Lymphocytesfor Stem Cell Transplant Patients with Refractory CMV Infections. ASH Annual Meeting Abstracts. 2011, 118 (21): #4033-

10.

Hanley PJ, Martinez C, Leung K, Savaldo B, Dotti G, Gee AP, Rooney CM, Heslop HE, Krance RA, Shpall EJ: Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes. ASH Annual Meeting Abstracts. 2011, 118 (21): #155-

11.

Yin Q, Zha X, Yang L, Chen S, Zhou Y, Wu X, Li Y: Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer. J Hematol Oncol. 2011, 4: 2-10.1186/1756-8722-4-2.PubMedCentralCrossRefPubMed

12.

Ochi T, Fujiwara H, Okamoto S, Asai H, Miyazaki Y, Shirakata T, Mineno J, Kuzushima K, Shiku H, Yasukawa M: Redirected CD4+ T Cells Using WT1-Specific T-Cell Receptor Gene Transfer Can Supply Multifactorial Help to Enhance the Anti-Leukemia Reactivity Mediated by Similarly Redirected CD8+ T Cells Using the Identical Gene Transfer. ASH Annual Meeting Abstracts. 2011, 118 (21): #645-

13.

Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR: Generation and Signaling Function of CD19 Chimeric Antigen Receptor Modified CD8+ T Cells Derived From Virus-Specific Central Memory Cells for Adoptive Therapy After Allogeneic Hematopoietic Stem Cell Transplant. ASH Annual Meeting Abstracts. 2011, 118 (21): #2978-

14.

Cartellieri M, Michalk I, von Bonin M, Krüger T, Stamova S, Koristka S, Arndt C, Feldmann A, Schmitz M, Wermke M: Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Acute Myeloid Leukemia. ASH Annual Meeting Abstracts. 2011, 118 (21): #2618-

Title: T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting
Author: Yangqiu Li
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue Special Issue 1/2012
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-5-S1-A3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2012

Restoration of T cell tolerance in primary ITP

Targeted therapy in head/neck and gastric cancers

Overcoming Gleevec-resistance by blocking oncogene addiction in malignant hematologic cells

Utilizing CD30 expression as a rational target for therapy of lymphoma

Targeting p53 by small molecule p53 activators in multiple myeloma

Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer